{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:06:21Z","timestamp":1792357581767,"version":"4.4.0"},"reference-count":243,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"publisher","award":["148442, 2016"],"award-info":[{"award-number":["148442, 2016"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01215","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T02:12:06Z","timestamp":1506651126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer"],"prefix":"10.3389","volume":"8","author":[{"given":"Isobel S.","family":"Okoye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokrollah","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/334395a0","article-title":"T-cell antigen receptor genes and T-cell recognition","volume":"334","author":"Davis","year":"1988","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4049\/jimmunol.167.3.1137","article-title":"Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells","volume":"167","author":"Piccirillo","year":"2001","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.4049\/jimmunol.1101649","article-title":"Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction","volume":"187","author":"Kastenmuller","year":"2011","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1073\/pnas.1103782108","article-title":"CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis","volume":"108","author":"McNally","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1084\/jem.20132577","article-title":"Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection","volume":"211","author":"Penaloza-MacMaster","year":"2014","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1126\/science.aaa2148","article-title":"Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection","volume":"347","author":"Penaloza-MacMaster","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1128\/JVI.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosanto","year":"2012","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.4049\/jimmunol.1100038","article-title":"Inhibitory receptors on lymphocytes: insights from infections","volume":"188","author":"Odorizzi","year":"2012","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","article-title":"CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1","volume":"72","author":"Fourcade","year":"2012","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.173.5.1099","article-title":"Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes","volume":"173","author":"Peters","year":"1991","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1073\/pnas.0502393102","article-title":"HIV-1-specific IFN-gamma\/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells","volume":"102","author":"Zimmerli","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cyto.a.20643","article-title":"Phenotype and function of human T lymphocyte subsets: consensus and issues","volume":"73","author":"Appay","year":"2008","journal-title":"Cytometry A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.4049\/jimmunol.175.7.4686","article-title":"Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L","volume":"175","author":"Bachmann","year":"2005","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","article-title":"Inhibitory receptors beyond T cell exhaustion","volume":"6","author":"Fuertes Marraco","year":"2015","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/87720","article-title":"Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in na\u00efve cells","volume":"2","author":"Kaech","year":"2001","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fimmu.2013.00455","article-title":"Inhibitory receptor expression depends more dominantly on differentiation and activation than \u201cexhaustion\u201d of human CD8 T cells","volume":"4","author":"Legat","year":"2013","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","article-title":"A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection","volume":"31","author":"Shin","year":"2009","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and epigenetic regulation of PD-1 expression","volume":"196","author":"Bally","year":"2016","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-to enhance CD8+ cytolytic T cell responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1245\/s10434-014-3671-0","article-title":"Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma","volume":"21","author":"Jiang","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"737389","DOI":"10.1155\/2015\/737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1200\/JCO.2012.47.1946","article-title":"Ipilimumab administration in patients with advanced melanoma and hepatitis B and C","volume":"31","author":"Sharma","year":"2013","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1200\/JCO.2012.46.5831","article-title":"Ipilimumab-induced hepatitis C viral suppression","volume":"31","author":"Minter","year":"2013","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1200\/JCO.2011.36.9199","article-title":"Case report: response to ipilimumab in a patient with HIV with metastatic melanoma","volume":"29","author":"Burke","year":"2011","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","article-title":"A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells","volume":"166","author":"Singer","year":"2016","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4172\/2155-9899.S12-004","article-title":"T cell co-inhibitory receptors-functions and signalling mechanisms","author":"Thaventhiran","year":"2013","journal-title":"J Clin Cell Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1085146","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 expression on dendritic cells suppresses CD8 + T cell function and anti-tumor immunity","volume":"5","author":"Lim","year":"2015","journal-title":"Oncoimmunology"},{"key":"B55","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1182\/blood-2009-02-203141","article-title":"PD-1 on dendritic cells impedes innate immunity against bacterial infection","volume":"113","author":"Yao","year":"2009","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445DS1","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat Immunol"},{"key":"B65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/JVI.01579-09","article-title":"Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion","volume":"84","author":"Blackburn","year":"2010","journal-title":"J Virol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2013.10.022","article-title":"Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors","volume":"146","author":"Kroy","year":"2014","journal-title":"Gastroenterology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/infdis\/jiv226","article-title":"Elevated expression of CD160 and 2B4 defines a cytolytic HIV-specific CD8+ T-cell population in elite controllers","volume":"212","author":"Pombo","year":"2015","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e105703","DOI":"10.1371\/journal.pone.0105703","article-title":"Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules","volume":"9","author":"Raziorrouh","year":"2014","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1004251","DOI":"10.1371\/journal.ppat.1004251","article-title":"T-bet and eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection","volume":"10","author":"Buggert","year":"2014","journal-title":"PLoS Pathog"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int"},{"key":"B78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molimm.2007.07.038","article-title":"PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients","volume":"45","author":"Peng","year":"2008","journal-title":"Mol Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/ni1009","article-title":"Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells","volume":"4","author":"Kaech","year":"2003","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1128\/JVI.80.7.3532-3540.2006","article-title":"Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection","volume":"80","author":"Boettler","year":"2006","journal-title":"J Virol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-2249.2006.03022.x","article-title":"CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients-reversal by highly active anti-retroviral therapy (HAART)","volume":"143","author":"Colle","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1743-422X-7-207","article-title":"Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment","volume":"7","author":"Lv","year":"2010","journal-title":"Virol J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.21365","article-title":"Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence","volume":"44","author":"Golden-Mason","year":"2006","journal-title":"Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/eji.200839059","article-title":"Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection","volume":"39","author":"Zhang","year":"2009","journal-title":"Eur J Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur J Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"52","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e47648","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection","volume":"7","author":"Nebbia","year":"2012","journal-title":"PLoS One"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e1000947","DOI":"10.1371\/journal.ppat.1000947","article-title":"Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation","volume":"6","author":"Bengsch","year":"2010","journal-title":"PLoS Pathog"},{"key":"B90","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J Virol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J Clin Invest"},{"key":"B92","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","article-title":"Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization","volume":"134","author":"Nakamoto","year":"2008","journal-title":"Gastroenterology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cei.12158","article-title":"Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C","volume":"174","author":"Sumida","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1002840","DOI":"10.1371\/journal.ppat.1002840","article-title":"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction","volume":"8","author":"Peretz","year":"2012","journal-title":"PLoS Pathog"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1042\/BST0351405","article-title":"PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription","volume":"35","author":"Palvimo","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1005349","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.2422","article-title":"Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression","volume":"17","author":"Elahi","year":"2011","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e88884","DOI":"10.1371\/journal.pone.0088884","article-title":"Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy","volume":"9","author":"Poonia","year":"2014","journal-title":"PLoS One"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e40146","DOI":"10.1371\/journal.pone.0040146","article-title":"Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection","volume":"7","author":"Sakhdari","year":"2012","journal-title":"PLoS One"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e101441","DOI":"10.1371\/journal.pone.0101441","article-title":"CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV\/HIV co-infected individuals","volume":"9","author":"Kared","year":"2014","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e59302","DOI":"10.1371\/journal.pone.0059302","article-title":"Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV\/HCV coinfection","volume":"8","author":"Feuth","year":"2013","journal-title":"PLoS One"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/eji.201040340","article-title":"HCV-specific T cells in HCV\/HIV co-infection show elevated frequencies of dual Tim-3\/PD-1 expression that correlate with liver disease progression","volume":"40","author":"Vali","year":"2010","journal-title":"Eur J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/QAD.0b013e32836285e4","article-title":"Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus\/HIV coinfection as compared to hepatitis C virus or HIV monoinfection","volume":"27","author":"Saha","year":"2013","journal-title":"AIDS"},{"key":"B108","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J Clin Invest"},{"key":"B113","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e30852","DOI":"10.1371\/journal.pone.0030852","article-title":"Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization","volume":"7","author":"Baitsch","year":"2012","journal-title":"PLoS One"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J Clin Invest"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1189\/jlb.0513293","article-title":"At the bedside: adoptive cell therapy for melanoma-clinical development","volume":"95","author":"Weber","year":"2014","journal-title":"J Leukoc Biol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"B122","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/cmi.2010.28","article-title":"Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer","volume":"7","author":"Zhang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0167-5699(99)01444-9","article-title":"Faces and phases of human CD8+ T-cell development","volume":"20","author":"Hamann","year":"1999","journal-title":"Immunol Today"},{"key":"B127","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nri1254","article-title":"Human CD8(+) T-cell differentiation in response to viruses","volume":"3","author":"van Lier","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/JID.2015.404","article-title":"Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase","volume":"136","author":"Inozume","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1172\/JCI40070","article-title":"BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination","volume":"120","author":"Derr\u00e9","year":"2010","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","article-title":"A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1","volume":"75","author":"Ngiow","year":"2015","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.86014","article-title":"T cell Bim levels reflect responses to anti-PD-1 cancer therapy","volume":"1","author":"Dronca","year":"2016","journal-title":"JCI Insight"},{"key":"B132","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4161\/onci.20823","article-title":"PD-1 and BTLA and CD8+ T-cell \u201cexhaustion\u201d in cancer: \u201cexercising\u201d an alternative viewpoint","volume":"1","author":"Haymaker","year":"2012","journal-title":"Oncoimmunology"},{"key":"B134","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/2326-6066.CIR-14-0159","article-title":"Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells","volume":"3","author":"Berrien-Elliott","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B135","unstructured":"US Food and Drug Administration, The Center for Drug Evaluation and Research2011"},{"key":"B136","unstructured":"Study of Tremelimumab in Patients with Advanced Solid Tumors2017"},{"key":"B137","unstructured":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant Mesothelioma2017"},{"key":"B138","unstructured":"A Phase 1 Study of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Solid Tumors2017"},{"key":"B139","unstructured":"Evaluating Immune Therapy, Duravalumab (MEDI4736) with Tremelimumab for Relapsed\/Refractory Germ Cell Tumors2017"},{"key":"B140","unstructured":"Lenalidomide and Pidilizumab in Treating Patients with Relapsed or Refractory Multiple Myeloma2017"},{"key":"B141","unstructured":"Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma2017"},{"key":"B142","unstructured":"A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-Operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)2017"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B144","unstructured":"MPDL3280A and Stereotactic Ablative Radiotherapy in Patients with Non-small Cell Lung Cancer2017"},{"key":"B145","unstructured":"MEDI4736 (Anti PD-L1) Combined with Gefitinib in Subjects with Non-Small Cell Lung Cancer (NSCLC)2017"},{"key":"B146","unstructured":"U.S. Food and Drug Administration, The Center for Drug Evaluation and Research2014"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e1100789","DOI":"10.1080\/2162402X.2015.1100789","article-title":"Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma","volume":"5","author":"Schlosser","year":"2016","journal-title":"Oncoimmunology"},{"key":"B148","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/eji.201646583","article-title":"Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer","volume":"47","author":"van Hooren","year":"2016","journal-title":"Eur J Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B151","unstructured":"Safety and Efficacy of MBG453 as Single Agent and in Combination with PDR001 in Patients with Advanced Malignancies2017"},{"key":"B152","unstructured":"Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 in Patients with Advanced Malignancies2017"},{"key":"B153","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J Transl Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J Transl Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1517\/14712598.2011.540563","article-title":"The CD4-like molecule LAG-3, biology and therapeutic applications","volume":"15","author":"Sierro","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients \u2013 report of a phase I\/IIa clinical trial","volume":"22","author":"Legat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B158","unstructured":"Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma2017"},{"key":"B159","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/COH.0000000000000093","article-title":"Animal models for viral infection and cell exhaustion","volume":"9","author":"McGary","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"B160","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1182\/blood-2006-04-010637","article-title":"CTLA-4 blockade decreases TGF-\u03b2, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques","volume":"108","author":"Hryniewicz","year":"2006","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e77780","DOI":"10.1371\/journal.pone.0077780","article-title":"PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads","volume":"8","author":"Seung","year":"2013","journal-title":"PLoS One"},{"key":"B163","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.4049\/jimmunol.1400961","article-title":"Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques","volume":"193","author":"Fujita","year":"2014","journal-title":"J Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"21","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"B166","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000449342","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: 2017 update","volume":"6","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"B170","doi-asserted-by":"publisher","first-page":"TS504","DOI":"10.1200\/JCO.2017.35.4_suppl.TPS504","article-title":"KEYNOTE-224: phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma","volume":"35","author":"Zhu","year":"2017","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"TS503","DOI":"10.1200\/JCO.2017.35.4_suppl.TPS503","article-title":"KEYNOTE-240: randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma","volume":"35","author":"Finn","year":"2017","journal-title":"J Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B174","unstructured":"Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery2017"},{"key":"B175","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B177","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B178","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska","year":"2015","journal-title":"Mol Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"B181","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CCO.0000000000000295","article-title":"Side-effects of checkpoint inhibitor-based combination therapy","volume":"28","author":"Kourie","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B183","unstructured":"Safety and Efficacy of MBG453 as Single Agent and in Combination with PDR001 in Patients with Advanced Malignancies2017"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"B186","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/CCO.0000000000000291","article-title":"Immune-mediated respiratory adverse events of checkpoint inhibitors","volume":"28","author":"Tabchi","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/toxins6030914","article-title":"Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an \u201cinnocent bystander\u201d","volume":"6","author":"Gelao","year":"2014","journal-title":"Toxins (Basel)"},{"key":"B190","first-page":"71","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2010"},{"key":"B191","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B192","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CCO.0000000000000292","article-title":"Checkpoint inhibitors and gastrointestinal immune-related adverse events","volume":"28","author":"Pernot","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B193","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1756283X16646709","article-title":"Ipilimumab-induced colitis: experience from a tertiary referral center","volume":"9","author":"O\u2019Connor","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-015-1074-7","article-title":"Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis","volume":"15","author":"Venditti","year":"2015","journal-title":"BMC Cancer"},{"key":"B195","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/CMR.0000000000000252","article-title":"Anti-PD1-induced collagenous colitis in a melanoma patient","volume":"26","author":"Baroudjian","year":"2016","journal-title":"Melanoma Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-208102","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B197","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"B198","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"B199","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B200","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3928\/23258160-20150610-10","article-title":"Ipilimumab-associated retinopathy","volume":"46","author":"Crews","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"B201","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","article-title":"Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma","volume":"6","author":"Hahn","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"B202","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"B203","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of nivolumab","volume":"11","author":"Vandiver","year":"2016","journal-title":"Target Oncol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B205","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother cancer"},{"key":"B206","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2326-6066.CIR-15-0035","article-title":"Ipilimumab-induced encephalopathy with a reversible splenial lesion","volume":"3","author":"Conry","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B209","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1479-5876-10-146","article-title":"Biomarkers on melanoma patient T cells associated with ipilimumab treatment","volume":"10","author":"Wang","year":"2012","journal-title":"J Transl Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B215","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","article-title":"Managing adverse events with immune checkpoint agents","volume":"22","author":"Dadu","year":"2016","journal-title":"Cancer J"},{"key":"B216","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B217","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-11-2197","article-title":"Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma","volume":"18","author":"Luke","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"B219","unstructured":"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients with Advanced Tumors and Lymphomas2017"},{"key":"B220","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"B221","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2","volume":"105","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","article-title":"From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway","volume":"21","author":"Zhan","year":"2016","journal-title":"Drug Discov Today"},{"key":"B223","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/cmdc.201500566","article-title":"Cancer immunotherapy: selected targets and small-molecule modulators","volume":"11","author":"Weinmann","year":"2016","journal-title":"ChemMedChem"},{"key":"B224","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.4172\/2376-0419.1000e119","article-title":"Do we need small molecule inhibitors for the immune checkpoints?","volume":"1","author":"Barakat","year":"2014","journal-title":"J Pharm Care Heal Syst"},{"key":"B225","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/13543776.2016.1206527","article-title":"Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)","volume":"26","author":"Zarganes-Tzitzikas","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"B226","doi-asserted-by":"publisher","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"B227","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B228","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"B229","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"B230","doi-asserted-by":"publisher","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci Immunol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/infdis\/jiu501","article-title":"A jekyll and hyde profile: type 1 interferon signaling plays a prominent role in the initiation and maintenance of a persistent virus infection","volume":"212","author":"Oldstone","year":"2015","journal-title":"J Infect Dis"},{"key":"B232","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-016-1799-4","article-title":"Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155","volume":"65","author":"Zhang","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B233","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2011-11-389585","article-title":"Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection","volume":"119","author":"Elahi","year":"2012","journal-title":"Blood"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/v2071382","article-title":"Targeting microRNA-122 to treat hepatitis C virus infection","volume":"2","author":"Jopling","year":"2010","journal-title":"Viruses"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/ajg.2011.161","article-title":"Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection","volume":"106","author":"Bihrer","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"e26971","DOI":"10.1371\/journal.pone.0026971","article-title":"Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma","volume":"6","author":"Bihrer","year":"2011","journal-title":"PLoS One"},{"key":"B237","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mc.20712","article-title":"Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis","volume":"50","author":"Xu","year":"2011","journal-title":"Mol Carcinog"},{"key":"B238","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1158\/1078-0432.CCR-13-1326","article-title":"miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression","volume":"19","author":"Tang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B239","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1476-4598-9-169","article-title":"MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation","volume":"9","author":"Yu","year":"2010","journal-title":"Mol Cancer"},{"key":"B240","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ni.3755","article-title":"The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection","volume":"18","author":"Moffett","year":"2017","journal-title":"Nat Immunol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nri.2016.98","article-title":"T cell responses: defective mitochondria disrupt CD8+ T cells","volume":"16","author":"Leavy","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B243","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T02:12:43Z","timestamp":1506651163000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":243,"alternative-id":["10.3389\/fimmu.2017.01215"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01215","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"article-number":"1215"}}